Please use this identifier to cite or link to this item: http://hdl.handle.net/1942/39035
Full metadata record
DC FieldValueLanguage
dc.contributor.authorOreja-Guevara, C.-
dc.contributor.authorBenedict, R. H.-
dc.contributor.authorComi, G.-
dc.contributor.authorCutter, G.-
dc.contributor.authorKister, I.-
dc.contributor.authorSiva, A.-
dc.contributor.authorWiendl, H.-
dc.contributor.authorVAN WIJMEERSCH, Bart-
dc.contributor.authorWuerfel, J.-
dc.contributor.authorEl Azzouzi, B.-
dc.contributor.authorBuffels, R.-
dc.contributor.authorDirks, P.-
dc.contributor.authorKuenzel, T.-
dc.contributor.authorVermersch, P.-
dc.date.accessioned2022-12-15T07:33:12Z-
dc.date.available2022-12-15T07:33:12Z-
dc.date.issued2022-
dc.date.submitted2022-12-09T12:55:50Z-
dc.identifier.citationMultiple Sclerosis Journal, 28 (S3) , p. 327 -329-
dc.identifier.urihttp://hdl.handle.net/1942/39035-
dc.description.sponsorshipF. Hoffmann-La Roche Ltd; Articulate Science, UK-
dc.language.isoen-
dc.publisherSAGE PUBLICATIONS LTD-
dc.titleEfficacy and safety of ocrelizumab is maintained in patients with RRMS with suboptimal response to prior disease-modifying therapies: 4-year NEDA data from CASTING-LIBERTO-
dc.typeJournal Contribution-
local.bibliographicCitation.conferencedateOCT 26-28, 2022-
local.bibliographicCitation.conferencename38th Congress of the-
local.bibliographicCitation.conferencenameEuropean-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis-
local.bibliographicCitation.conferenceplaceAmsterdam, NETHERLANDS-
dc.identifier.epage329-
dc.identifier.issueS3-
dc.identifier.spage327-
dc.identifier.volume28-
local.format.pages3-
local.bibliographicCitation.jcatM-
local.publisher.place1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND-
local.type.refereedRefereed-
local.type.specifiedMeeting Abstract-
dc.identifier.isi000866540801286-
local.provider.typewosris-
local.description.affiliation[Oreja-Guevara, C.] Hosp Clin San Carlos, Madrid, Spain.-
local.description.affiliation[Benedict, R. H.] SUNY Buffalo, Dept Neurol, Jacobs Sch Med & Biomed Sci, Buffalo, NY USA.-
local.description.affiliation[Comi, G.] Univ Vita Salute San Raffaele, Milan, Italy.-
local.description.affiliation[Cutter, G.] Univ Alabama Birmingham, Dept Biostat, Birmingham, AL USA.-
local.description.affiliation[Kister, I.] NYU, Langone Med Ctr, Multiple Sclerosis Comprehens Care Ctr, New York, NY USA.-
local.description.affiliation[Siva, A.] Istanbul Univ, Cerrahpasa Med Sch, Istanbul, Turkey.-
local.description.affiliation[Wiendl, H.] Univ Munster, Dept Neurol, Inst Translat Neurol, Munster, Germany.-
local.description.affiliation[Van Wijmeersch, B.] Hasselt Univ, Univ MS Ctr, Hasselt, Belgium.-
local.description.affiliation[Wuerfel, J.] Univ Basel, Dept Biomed Engn, Med Image Anal Ctr MIAC AG, Basel, Switzerland.-
local.description.affiliation[Wuerfel, J.] Univ Magdeburg, Dept Neuroradiol, Magdeburg, Germany.-
local.description.affiliation[El Azzouzi, B.; Buffels, R.; Dirks, P.; Kuenzel, T.] F Hoffmann La Roche Ltd, Basel, Switzerland.-
local.description.affiliation[Vermersch, P.] Univ Lille, Inserm LilNCog U1172, CHU Lille, FHU Precise, Lille, France.-
local.uhasselt.internationalyes-
item.fulltextWith Fulltext-
item.contributorOreja-Guevara, C.-
item.contributorBenedict, R. H.-
item.contributorComi, G.-
item.contributorCutter, G.-
item.contributorKister, I.-
item.contributorSiva, A.-
item.contributorWiendl, H.-
item.contributorVAN WIJMEERSCH, Bart-
item.contributorWuerfel, J.-
item.contributorEl Azzouzi, B.-
item.contributorBuffels, R.-
item.contributorDirks, P.-
item.contributorKuenzel, T.-
item.contributorVermersch, P.-
item.accessRightsOpen Access-
item.fullcitationOreja-Guevara, C.; Benedict, R. H.; Comi, G.; Cutter, G.; Kister, I.; Siva, A.; Wiendl, H.; VAN WIJMEERSCH, Bart; Wuerfel, J.; El Azzouzi, B.; Buffels, R.; Dirks, P.; Kuenzel, T. & Vermersch, P. (2022) Efficacy and safety of ocrelizumab is maintained in patients with RRMS with suboptimal response to prior disease-modifying therapies: 4-year NEDA data from CASTING-LIBERTO. In: Multiple Sclerosis Journal, 28 (S3) , p. 327 -329.-
crisitem.journal.issn1352-4585-
crisitem.journal.eissn1477-0970-
Appears in Collections:Research publications
Files in This Item:
File Description SizeFormat 
Efficacy and safety of ocrelizumab is maintained in patients with RRMS with.pdfPublished version7.08 MBAdobe PDFView/Open
Show simple item record

Google ScholarTM

Check


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.